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Detection of Ligand-induced Conformational Changes in
the Activation Loop of Aurora-A Kinase by PELDOR
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The structure of protein kinases has been extensively studied
by protein crystallography. Conformational movement of the
kinase activation loop is thought to be crucial for regulation of
activity ; however, in many cases the position of the activation
loop in solution is unknown. Protein kinases are an important
class of therapeutic target and kinase inhibitors are classified
by their effect on the activation loop. Here, we report the use
of pulsed electron double resonance (PELDOR) and site-direct-
ed spin labeling to monitor conformational changes through
the insertion of MTSL [S-(1-oxyl-2,2,5,5-tetramethyl-2,5-dihydro-
1H-pyrrol-3-yl)methyl methanesulfonothioate] on the dynamic
activation loop and a stable site on the outer surface of the
enzyme. The action of different ligands such as microtubule-as-
sociated protein (TPX2) and inhibitors could be discriminated
as well as their ability to lock the activation loop in a fixed con-
formation. This study provides evidence for structural adapta-
tions that could be used for drug design and a methodological
approach that has potential to characterize inhibitors in
development.
Protein kinases are signaling enzymes that are regulated by
molecular-switch mechanisms.[1,2] Different protein kinases
have very similar structures when active, but can adopt a varie-
ty of divergent conformations when inactive. One common
mechanism of kinase activation is phosphorylation of the acti-
vation loop, a dynamic region that spans a consensus se-
quence from Asp–Phe–Gly (DFG) to Ala–Pro–Glu (APE).[3] Active
kinases adopt a DFG-in conformation needed for the correct
placement of a catalytic Asp residue and for the central region
of the activation loop to form part of the binding site for pro-
tein and peptide substrates. Despite intensive studies of kinas-
es by X-ray crystallography,[4,5] there are few studies of confor-
mational dynamics of the activation loops in solution.
Protein kinases are frequently dysregulated in human dis-
ease and are a common target for the development of new
therapeutics. Most protein kinase inhibitors[6] compete for the
ATP binding site and are further classified as either Type I,
which bind to the kinase in its active state, or Type II, which
bind to an inactive DFG-out conformation of the kinase and
occupy an additional hydrophobic pocket within the active
site. However, validation of the effect of inhibitors requires de-
termination of the kinase-inhibitor structure by X-ray crystal-
lography, and some compounds that would be classified as
Type I based on their chemical structures induce DFG-flipped
conformations of the activation loop that resemble Type II[7–9]
inhibitors. Methods for analyzing the activation loop conforma-
tion in solution would be invaluable in the development and
characterization of kinase inhibitors, enabling classification in
the absence of crystal structures.[10–12]
Aurora kinases constitute a family of serine–threonine pro-
tein kinases whose localization and activities are precisely chor-
eographed as a cell progresses through mitosis.[13–15] They play
a major role in cell cycle progression and map to a chromo-
some region that is frequently amplified in tumors.[16] Aurora-A
is activated by phosphorylation on Thr-288 and by the micro-
tubule-associated protein, TPX2.[17] Crystal structures suggest
that this involves a lever-arm-like movement of the Aurora-A
activation loop from a relatively mobile conformation to a con-
formation that is stabilized by being hooked onto a short heli-
cal region in TPX2 (Figures 1A and 1B). However, this model
has yet to be probed in solution.
Here, we investigate the application of site-directed spin la-
beling (SDSL) and pulsed electron–electron double resonance
(PELDOR or DEER) spectroscopy[18–19] to measure distances be-
tween pairs of spin labels attached to Aurora-A in the presence
or absence of ligands and the TPX2 protein. PELDOR separates
dipole–dipole coupling between spins, which is inversely pro-
portional to the cube of their distance. It can measure distan-
ces between spin labels on the nanometer scale (1.5–
10 nm).[20] Dipolar spectroscopy has been successfully em-
ployed to study kinases.[21–23] However, to the best of our
knowledge, this approach has not been applied to a kinase ac-
tivation loop.
We analyzed the structure of Aurora-A kinase to identify
suitable pairs of sites for site-specific labeling. Glu170 on the
aB-helix of the kinase N-lobe was identified as a stable posi-
tion that does not respond to inhibitors, and Ser284 and
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Thr288 were chosen on the activation loop (Figure 1A). These
sites were mutated to cysteine in the background of an
Aurora-A mutant (C290A, C393A) that lacks other surface cys-
teines. Recombinant proteins were labeled with MTSL [S-(1-
oxyl-2,2,5,5-tetramethyl-2,5-dihydro-1H-pyrrol-3-yl)methyl
methanesulfonothioate] (Figure 1C). We designed the system
to be suitable for the detection of changes in the activation
loop.
By using SDSL and PELDOR spectroscopy, distances were
measured initially in the absence of a ligand. The PELDOR
traces for MTSL-labeled Aurora-A variants E170C/T284C and
E170C/T288C showed a shallow oscillation, indicative of a wide
distribution of conformational states. The extracted distance
distribution showed a dominant mean distance at 28 a (Fig-
ure 1D). Based on the acquisition window, the data are of suffi-
cient quality to establish from the distribution a reliable mean
and width with approximate shape. The wide distribution sug-
gests spatial disorder of the Aurora-A kinase activation loop,
consistent with crystal structures, as well as multiple internal
rotamers of the MTSL.[24]
Comparison was made to the distribution created from
a rotamer library[25] using PDB:1OL7. Although, a similar distri-
bution width was found, the mean distance was offset in the
case of the E170C/T288C variant, suggesting a difference in
the conformation of the activation loop in solution. Continu-
ous-wave electron paramagnetic resonance (EPR) spectra
showed no significant dipolar broadening of the EPR line
width, indicating that distances <15 a are not significantly
populated (Figure S2). Little difference was observed between
the apo enzyme and with ADP (present in the crystal struc-
tures) for the E170C/T288C variant ; however, the E170C/T284C
variant showed a shift of the mean distance to 24 a.
The effect of TPX2 on the activation loop of Aurora-A phos-
phorylated on T288 was investigated with a PELDOR experi-
ment on MTSL-labeled E170C/T284C Aurora-A. This resulted in
a pronounced change in the distance distribution compared to
the apo enzyme, consistent with a different conformational
state of the activation loop (Figure 1D). There was a sharp
peak in the distance distribution at 34 a, which is in reasona-
ble agreement with the conformational change observed in
the crystal structure. Small-molecule inhibitors of Aurora kinas-
es, such as compounds 1 and 5, have been identified as poten-
tial cancer therapeutics,[26] and clinical trials are ongoing (Fig-
ure 2A).[27] To validate the site-directed-labeling EPR approach,
we tested imidazo[1,2-a]pyrazine-based (compounds 2 and
3)[28] and imidazo[4,5-b]pyridine-based inhibitors (compounds 4
and 5),[29] which dock into the ATP binding site but do not
affect the activation loop, as observed by X-ray crystallography
(Figures 2B and S3).[28,29] The results showed little change in
the mean and width of the distribution (Figure 2C), indicating
minimal perturbation of the activation loop, a distinct differ-
ence compared to TPX2.
A crystal structure of compound 1[30] bound to Aurora-A
(PDB:2WTV) showed that the drug induces an ordered and
closed, inactive, conformation of the Aurora-A activation loop
(Figure 2D).[7] The conformational change in the activation
loop moves the Ca of Val279 by approximately 19 a compared
with its position in the ADP-bound structure. However, other
crystal structures (Figure 2E) showed an alternative conforma-
tion of Aurora-A bound to compound 1 (PDB codes:2WTW and
2X81).[7, 31] The specific conformation induced by MLN8237, an
Aurora-A inhibitor closely related to compound 1, might ex-
plain its activity in neuroblastoma cells.[32] The conformation of
Figure 1. A) Cartoon of Aurora-A kinase (PDB:1OL7) showing the MTSL label-
ing sites (Glu170, Thr288 and Ser284). B) Cartoon of Aurora-A with TPX
bound (PDB:1OL5) C) The chemical structure of the MTSL label and the
product of its reaction with a cysteine residue on Aurora-A. D) Background-
corrected PELDOR traces at 9 GHz for MTSL-labeled Aurora-A kinase variants
and with a four-fold excess of ADP and TPX2 (left column). Form factor fits
are given as a dashed line. Distance distributions derived using Tikhonov
regularization (a=100) (right column). Rotamer library-derived distributions
are given as dashed lines. All PELDOR traces before background correction
are given in Figure S1.
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the kinase in solution in the presence of the compound is an
open and important question.
PELDOR experiments on MTSL-labeled E170C/T288C Aurora-
A in the presence of compound 1 revealed a clear change in
the oscillation, reflected by a change in the major peak of the
distance distribution (Figure S5). The distance distribution ap-
pears to narrow with the presence of compound 1 (absent
with compounds 2–5), suggesting a greater order of the con-
formation of the activation loop. Further experiments at
34 GHz (Figure 2F) gave a well-defined oscillation and con-
firmed the result. The distribution is narrower and shifts to
a shorter dominant distance of 25 a, as compared to Aurora-A
alone.
Key measurements were repeated to evaluate changes in
MTSL-labeled Aurora-A E170C/S284C on ligand binding (Fig-
ure 2G). Upon addition of compound 1, we observed a change
in the mean distance and a narrowing of the distribution,
which is absent in the case of compound 5 (Figure S6). Inter-
estingly, the rotamer library produced with PDB:2WTV (Fig-
ure 2G, grey dash) showed a significant difference with
a mean distance of 42 a, suggesting the conformation of the
activation loop is more akin to the DFG-in state adopted in
PDB:2WTW, which differs from that induced by compounds 2–
5, because the N and C lobes of the kinase are twisted. There
is perhaps only a minor contribution from the DFG-up state in
PDB:2WTV. Subsequent addition of TPX2 caused a broad dis-
tance distribution profile, which is distinct from that of TPX2
and compound 1 alone, indicating a dynamic conformation
that results from the opposing tendencies of TPX2 and com-
pound 1 (Figure S7).
Recently, the structures of a number of mammalian kinases
bound to ligands and substrates have been solved using X-ray
crystallography. Although structures for open and closed forms
are available for certain kinases, it is becoming clear that they
occupy several conformational states, and that our knowledge
of these states in solution is poor. In particular, the dynamics
of the activation loop and how it responds to ligands is poorly
characterized. PELDOR is complementary to other biophysical
methods used to study kinase activation loops and holds
many advantages, such as the smaller size of their labels com-
pared to Fçrster resonance energy transfer (FRET) and no
issues with limitations of molecular weight or difficulties with
chemical exchange in NMR. However, one weakness of meth-
ods such as PELDOR and FRET is that the measurements are of
the synthetic modifications of the protein, not the main chains
and side chains of the amino acids. Indeed, the full extent of
the movement of the activation loop will be understood
through ongoing work by using molecular dynamics to imple-
ment the distance constraints provided by the PELDOR meas-
urements to model the full conformational change of the acti-
vation loop. Inarguably, a combination of approaches will be
required to solve this problem.
The studies here provide key information on adaptations to
inhibitor binding. Our results confirm that PELDOR is a suitable
approach to discriminate between different classes of ligand
that do, or do not, influence the conformation of the kinase.
Overall, the results suggest a correlation between the trends
Figure 2. A) Chemical structures of compounds 1 and 5. B) Cartoon of the
Aurora-A binding site for compound 5 in PDB:2X6G. C) Background-correct-
ed PELDOR traces at 9 GHz for MTSL-labeled Aurora-A E170C/T288C with
a four-fold excess of inhibitors (left column). Form factor fits are given as
a dashed line. Distance distributions derived using Tikhonov regularization
(a=100) (right column). D) Cartoon of the Aurora-A binding site of com-
pound 1 in PDB:2WTV. E) Cartoon of the Aurora-A binding site of com-
pound 1 in PDB:2WTW. F) The same as (C), but at 34 GHz. G) The same as (C)
for Aurora-A E170C/S284C. Rotamer library-derived distributions are given as
dashed lines. All PELDOR traces before background correction are given in
Figure S4.
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found for inhibitors and TPX2 with PELDOR spectroscopy and
the observed conformational changes in the activation loop as
judged by X-ray crystallography. Although the differences in
the mean of the PELDOR distributions for the inhibitors are
small, they show a clear trend and are able to discriminate
whether or not inhibitor binding to the ATP site influences the
activation loop. This work suggests that PELDOR spectroscopy
could be a potential method to classify inhibitors by their ef-
fects on the conformation of the kinase activation loop as well
as the study of native substrates in solution. Moreover, the
method has sufficient sensitivity to detect the influence of
TPX2 on the activation loop of Aurora-A in the absence of an
inhibitor, and shows that this is altered in the presence of com-
pound 1.
Our ultimate aim is to exploit the information gleaned from
these studies to generate plausible models of the structure
and dynamics of human kinases. This may enable the develop-
ment of inhibitors that exploit specific conformational states
that are not accessible for study by other methods.
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